In ER+ breast cancer cell lines, CDK9 targeting has been shown to reduce the level of MYC and MYB expression and E2-independent tumor cell proliferation (21, 22) but little information is available of the effectiveness of CDK9 inhibition in reducing tumor growth in vivo. The gene discussed is MYB; the disease is breast carcinoma.